CC16 predicts respiratory dysfunction and eosinophilic inflammation in severe asthma
Japan: CC16 (Club cell 16-kDa secretory protein) may help predict rapid FEV1 decline and enhanced eosinophilic inflammation in patients with severe asthma, a recent study has revealed.
In the study published in Respiratory Medicine, CC16 was shown to be inversely associated with T-helper 2 (Th2) biomarkers and the annual decline in forced expiratory volume in the first second (FEV1) in severe asthma patients. Clinicians may evaluate future and current severe asthma outcomes per baseline levels of CC16.
There are knowledge gaps in the potential role of CC16 in severe asthma phenotypes and type 2 inflammation, as well as the longitudinal effect of CC16 on exacerbation risk and pulmonary function tests in epidemiological studies. To fill this knowledge gap, Houman Goudarzi from Hokkaido University in Sapporo, Japan, and colleagues aimed to investigate whether serum CC16 is linked with eosinophilic inflammation in severe asthma patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.